Corti launches new FactsR system for clinical consultations
This system aims to lessen 'note bloat' driven by general-purpose AI by 65%, ensuring that medical records remain precise and relevant to the actual clinical conversation.
FactsR stands out from traditional large language model (LLM) pipelines adapted for healthcare by utilising Corti's recursive fact-first reasoning loop.
By minimising the need for post-visit edits and transforming passive transcripts into active clinical intelligence, FactsR paves the way for real-time decision support directly at the point of care.
Offered as a modular API, the system enables developers to integrate clinical-grade intelligence into healthcare applications, fostering safer AI experiences.
It allows for the creation of AI that delivers concise and accurate results, which clinicians can interact with during consultations.
FactsR operates in four key areas. Firstly, it listens and extracts structured clinical facts in real-time, such as symptoms and medications, during the consultation.
Secondly, each fact is vetted and refined through a specialised AI-driven feedback loop, ensuring accuracy and consistency.
Later on, clinicians have the opportunity to review and adjust the facts, maintaining control and complementing clinical judgement.
Lastly, the system generates electronic health record (EHR)-ready notes that are concise and free from irrelevant content, leading to reduced screen time and improved focus on the patient.
Corti.ai chief technology officer and co-founder Lars Maaløesaid: 'By breaking conversations into structured clinical facts and validating each one through recursive reasoning, FactsR elevates ambient documentation into a foundation for real-time clinical intelligence.
'When AI can listen, understand, and reason with medical context, it becomes more than a scribe - it becomes a trusted collaborator. With a developer-friendly API, we're enabling any healthtech company to embed this capability directly into their applications - safely, scalably, and in minutes.'
In October 2024, Corti announced a collaboration with US-based Tanner Health and its subsidiary Healthliant Ventures.
"Corti launches new FactsR system for clinical consultations" was originally created and published by Hospital Management, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
19 minutes ago
- CNN
On GPS: Will AI save the economy?
Massive spending on artificial intelligence is propping up the US economy. So will AI save us, or is it a bubble waiting to pop? Fareed speaks with journalist Derek Thompson, co-author of the bestseller "Abundance."
Yahoo
3 hours ago
- Yahoo
The US May Have Already Lost the AI Race to China Due to a Key Weakness
You might have heard of an "AI race" heating up between the US and China, a bitter rivalry between two global adversaries that could shape the direction of world history. At least, that's how some in the US feel. While China has repeatedly tried to establish a geopolitical friendship with the richest nation in the world, officials and pundits in the US have doubled down, reframing artificial intelligence as the 21st century's nuclear bomb. In the meantime, China may have gotten a massive lead — by actively investing in its power grid, while the United States' is quickly running out of capacity to power immensely power-hungry AI models. As Fortune reports, Americans who've had a look at China's technological development firsthand found that the two country's aren't even in the same league, given China's next-level power grid. "Energy is considered a solved problem," wrote Rui Ma, editor of the US publication Tech Buzz China. "Everywhere we went, people treated energy availability as a given," she continued. "This is a stark contrast to the US, where AI growth is increasingly tied to debates over data center power consumption and grid limitations." AI is a notoriously energy-intensive technology. The data centers powering large language models like ChatGPT are immense labyrinths of computer chips, which suck down resources like power and water in order to keep up with demand. As Fortune notes, this effectively makes electricity the key bottleneck for expanding AI infrastructure. That's caused some critical shortages in the US. Short on energy and hopped up on fantasies of an arms race, American companies are resorting to all kinds of bizarre strategies to get their juice. Elon Musk's xAI, for example, is running 35 portable methane gas generators in the parking lot of one of its main datacenters in Memphis, encircling nearby communities in a cloud of noxious smog. China has no such problems. In 2024, China was responsible for nearly 65 percent of the world's renewable energy construction, installing so many solar panels and wind turbines that it caused the country's CO2 emissions to drop for the first time — despite record-high demands for energy. Whether or not the US can catch up remains to be seen. President Donald Trump previously made an off-the-cuff remark about attaching coal power plants to data centers directly. It's an unfortunate conundrum in an age when energy demand in the US has never been higher. In the meantime, China keeps chugging along, seemingly unperturbed by any energy bottlenecks — and the Trump administration's posturing. More on AI: AI Datacenters Are Raising Nearby Residents' Electric Bills Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
1 Stock Down 40% This Year to Buy and Hold
Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio
